Additional potential clinical regulatory commercialization payments under agreement.

No definition available.

Name:	mgnx_AdditionalPotentialClinicalRegulatoryCommercializationPaymentsUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate potential development regulatory and sales milestone payments available to be earned under agreement.

+ References

No definition available.

+ Details

Name:	mgnx_AdditionalPotentialDevelopmentRegulatoryAndSalesMilestoneUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaboration and license agreement entered date.

+ References

No definition available.

+ Details

Name:	mgnx_CollaborationAndLicenseAgreementEnteredDate
Namespace Prefix:	mgnx_
Data Type:	us-types:dateStringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	mgnx_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix:	mgnx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Non-refundable up front payment.

+ References

No definition available.

+ Details

Name:	mgnx_NonRefundableUpFrontPayment
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Initial fee receivable from collaboration or license agreement.

+ References

No definition available.

+ Details

Name:	mgnx_NonRefundableUpfrontPaymentReceivable
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Potential license option fee and early development milestone fee.

+ References

No definition available.

+ Details

Name:	mgnx_PotentialLicenseOptionFeeAndEarlyDevelopmentMilestoneFee
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Portion of upfront fee allocated to agreement.

+ References

No definition available.

+ Details

Name:	mgnx_UpfrontFeeAllocatedToAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Period over which upfront payment is to be recognized.

+ References

No definition available.

+ Details

Name:	mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix:	mgnx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

+ Details

Name:	us-gaap_DeferredRevenueNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=mgnx_TakedaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Additional Information 1 (Detail) (USD $)	1 Months Ended	12 Months Ended		1 Months Ended
	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	May 31, 2014
License And Collaboration Agreements [Line Items]
Stock issued during period value, new issues		$ 76,716,000	$ 83,623,000
Stock issued during the period for new issue	1,800,000
Deferred revenue current		14,248,000us-gaap_DeferredRevenueCurrent	20,267,000us-gaap_DeferredRevenueCurrent
Deferred revenue non-current		16,472,000us-gaap_DeferredRevenueNoncurrent	7,136,000us-gaap_DeferredRevenueNoncurrent
Janssen Biotech Inc. [Member]
License And Collaboration Agreements [Line Items]
Collaboration agreement date		December 2014
Stock issued during period value, new issues		75,000,000
Stock issued during the period for new issue		1,923,077
Common stock price per share		$ 39.00
Nonrefundable upfront payment receivable		50,000,000
Clinical, regulatory and commercialization milestone payments		575,000,000
Recognized revenue under agreement		0
Deferred revenue		0
Takeda [Member]
License And Collaboration Agreements [Line Items]
Collaboration agreement date		May 2014
Recognized revenue under agreement		3,000,000
Deferred revenue		7,100,000
Nonrefundable upfront payment				15,000,000
License option fee and early development milestone		18,000,000
Development, regulatory and sales milestone payments		468,500,000
Amount allocated to agreement		10,000,000
Expected period of development		24 months
Deferred revenue current		5,000,000
Deferred revenue non-current		2,100,000
Takeda [Member] \| Research Collaboration And License Option Agreement [Member]
License And Collaboration Agreements [Line Items]
Collaboration agreement date		September 2014
Recognized revenue under agreement		5,000,000
Amount allocated to agreement		$ 5,000,000